Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group study (E2588)

Fifty-five patients with metastatic non-small cell lung cancer (NSCLC) were entered into this phase II randomized study for evaluating three new agents: gallium nitrate, amonafide and teniposide. The patients had to have ECOG performance status 0 or 1, no prior chemotherapy, and adequate hematologic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 1995-01, Vol.13 (2), p.137-141
Hauptverfasser:	Chang, A Y, Tu, Z N, Smith, J L, Bonomi, P, Smith, T J, Wiernik, P H, Blum, R
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - secondary Drugs, Investigational - administration & dosage Drugs, Investigational - adverse effects Drugs, Investigational - therapeutic use Female Gallium - administration & dosage Gallium - adverse effects Gallium - therapeutic use Humans Imides - administration & dosage Imides - adverse effects Imides - therapeutic use Infusions, Intravenous Isoquinolines - administration & dosage Isoquinolines - adverse effects Isoquinolines - therapeutic use Longitudinal Studies Lung Neoplasms - drug therapy Lung Neoplasms - mortality Male Middle Aged Naphthalimides Survival Rate Teniposide - administration & dosage Teniposide - adverse effects Teniposide - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!